s_150324_1a
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- fusion
- ZFTA_RELA
- e1_e2
- E2
- umap1_2d
- -5.089102397
- umap2_2d
- 0.163838672
- umap1_3d
- -0.735749026
- umap2_3d
- 1.95266286
- umap3_3d
- 0.610770611
- dataset
- EPN-Heidelberg
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.650
- INFLAMMATORY_RESPONSE+0.640
- TNFA_SIGNALING_VIA_NFKB+0.640
- IL6_JAK_STAT3_SIGNALING+0.610
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- HYPOXIA+0.560
- ALLOGRAFT_REJECTION+0.500
- COMPLEMENT+0.490
- KRAS_SIGNALING_UP+0.460
- IL2_STAT5_SIGNALING+0.450
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.570
- DNA_REPAIR-0.480
- MYC_TARGETS_V1-0.380
- E2F_TARGETS-0.330
- PROTEIN_SECRETION-0.280
- G2M_CHECKPOINT-0.260
- PEROXISOME-0.260
- MITOTIC_SPINDLE-0.140
- ADIPOGENESIS-0.130
- BILE_ACID_METABOLISM-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_0QYS36NR | EPN | EPN Tumor | 0.941 |
| 2 | BS_PJPGVD62 | Ependymoma NOS | — | 0.936 |
| 3 | BS_G1Y281HX | Neuroblastoma | — | 0.925 |
| 4 | BS_PJPGVD62 | EPN | EPN Tumor | 0.919 |
| 5 | BS_X91K8KMG | pilocytic astrocytoma | — | 0.918 |
| 6 | BS_0QYS36NR | Ependymoma NOS | — | 0.918 |
| 7 | SJEPD038_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.915 |
| 8 | SJEPD009_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.915 |
| 9 | BS_YY5B2XDD | pilocytic astrocytoma | — | 0.909 |
| 10 | BS_W97QQYKQ | Ganglioglioma | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.650 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.640 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.640 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.610 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| HYPOXIA | 0.560 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.460 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.450 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.430 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.420 | Inavolisib | — uncovered |
| COAGULATION | 0.420 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| APOPTOSIS | 0.410 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.330 | Idelalisib | — uncovered |